Publication

Role of Serology in the Coronavirus Disease 2019 Pandemic

Downloadable Content

Persistent URL
Last modified
  • 05/21/2025
Type of Material
Authors
    Sean Stowell, Emory UniversityJeannette Guarner, Emory University
Language
  • English
Date
  • 2020-10-15
Publisher
  • Oxford University Press for the Infectious Diseases Society of America
Publication Version
Copyright Statement
  • © The Author(s) 2020.
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 71
Issue
  • 8
Start Page
  • 1935
End Page
  • 1936
Abstract
  • In this issue of Clinical Infections Diseases, F Xiang et al present a serologic study of 85 nucleic acid test (NAT) SARS-CoV-2 positive patients and 24 NAT negative patients who had symptoms suspicious for COVID-191. Sixty controls were also evaluated and included healthy healthcare staff and patients with a variety of diseases from bacterial pneumonia to lung cancer. Serological testing consisted of an enzyme linked immunosorbent assay designed to detect IgM and IgG antibodies against the N protein of SARS-CoV-2. Serial examination of COVID-19 patients resulted in IgM seroreactivity by day 4 post symptom onset, which peaked by day 9. In contrast, IgG sharply increased 12 days after symptom onset; all NAT positive patients were positive for IgG 30 days post symptom onset. In patients with suspected COVID-19 who tested NAT negative, IgM antibodies were detected in 87.5% and IgG was present in 70.8%. In contrast, only 3 individuals in the control group tested positive for IgG but IgM positivity was not observed. The authors calculated a sensitivity for diagnosis of COVID19 using IgM of 77.3% and a specificity of 100% while for IgG the sensitivity was higher at 83.3% and the specificity was 95%.
Author Notes
Keywords
Research Categories
  • Biology, Microbiology
  • Health Sciences, Epidemiology
  • Health Sciences, Immunology

Tools

Relations

In Collection:

Items